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Summary  It  is  difﬁcult  to  distinguish  dengue  fever  from  other  febrile  illnesses  in  a
dengue-endemic  area.  This  issue  was  compounded  during  the  H1N1  2009  pandemic
of  inﬂuenza,  which  also  presents  as  a  febrile  illness.  This  ﬁrst  laboratory-conﬁrmed
case  of  co-infection  with  dengue  and  inﬂuenza  A  H1N1  2009  strain  in  Jeddah,  SaudiCo-infection;
Viral hemorrhagic fevers
Arabia,  highlights  the  importance  of  considering  co-infections  because  not  only  is
inﬂuenza  an  ongoing  concern  in  Jeddah,  but  several  viral  hemorrhagic  fever  viruses
circulate  in  this  region.
©  2012  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Ltd.  All  rights  reserved.
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engue  fever,  the  most  common  mosquito  borne
isease,  is  caused  by  one  of  the  four  serotypes  of
he dengue  virus  [1].  These  viruses  are  a  major
nternational public  health  problem  [2],  infect-
ng 50—100  million  people  worldwide  annually,
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oi:10.1016/j.jiph.2011.12.005ith  approximately  12,500—25,000  deaths  [3—5].
engue-infected  patients  present  with  a ﬂu-like
llness  with  a  myriad  of  clinical  features;  infants
nd young  children  may  have  a fever  with  rash,
hereas older  children  and  adults  may  have  either
 mild  fever  or  the  classical  disease  with  high
ever, severe  headache,  pain  behind  the  eyes,  mus-
le and  joint  pains,  and  rash.  Potentially  serious
omplications  of  dengue  fever,  including  dengue
emorrhagic fever  (DHF)  and  dengue  shock  syn-
rome  (DSS),  can  develop  [2,6].
Inﬂuenza  is  a  serious  public  health  problem  that
s characterized  by  a sudden  onset  of  high  fever,
 Sciences. Published by Elsevier Ltd. All rights reserved.
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cough,  headache,  muscle  and  joint  pain,  severe
malaise,  sore  throat  and  a  runny  nose.  Inﬂuenza
viruses circulate  in  every  part  of  the  world  and
annually cause  epidemics  during  the  autumn  and
winter in  temperate  regions;  in  some  tropical  coun-
tries, inﬂuenza  viruses  circulate  throughout  the
year, with  one  or  two  peaks  during  the  rainy  sea-
sons. Worldwide,  these  annual  epidemics  result  in
approximately  3—5  million  cases  of  severe  illness
and  approximately  250,000—500,000  deaths  [7].
April 2009  marked  the  emergence  of  a novel
inﬂuenza A  H1N1  virus  infection  in  the  USA  [8].  After
spreading  throughout  the  USA  and  Canada  [9,10]
the virus  spread  globally,  and  by  11th  June,  the
WHO declared  a  phase  6  pandemic  [11].  The  ﬁrst
case of  H1N1  in  Saudi  Arabia  emerged  in  early  June,
and since  then,  the  H1N1  has  spread  throughout  the
country.
Concurrent  outbreaks  of  inﬂuenza  and  dengue
fever have  been  reported  in  various  tropical  coun-
tries and  territories,  including  Burma  [12],  India
[13], Thailand  [14]  and  Puerto  Rico  [15],  leading  to
the delayed  recognition  of  the  presence  of  one  or
the other  disease  in  the  community.  Both  dengue
fever  and  inﬂuenza  have  a  wide  range  of  clinical
presentations with  many  overlapping  features,  and
this overlap  hinders  the  differentiation  of  the  two
diseases.
In this  report,  we  discuss  the  diagnostic  chal-
lenge with  regard  to  the  clinical  proﬁle  of  a case
of laboratory-conﬁrmed  co-infection  with  dengue
virus and  pandemic  H1N1  with  persistent  viral
shedding.
Clinical proﬁle
A  44-year-old  info-tech  worker  presented  to  a  ter-
tiary care  hospital  in  Jeddah  with  complaints  of
productive  cough  and  fever  for  2  weeks.  At  the  time
of admission  to  the  hospital,  the  patient’s  tem-
perature  was  40 ◦C,  and  his  blood  pressure  was
120/91 mmHg;  he  complained  of  headache,  myal-
gia, chills,  sore  throat,  nausea  and  anorexia.  The
patient also  had  a  previous  history  of  asthma.
The chest  examinations  revealed  disperse  rhonchi,
especially  in  the  lower  left  and  right  mid  zones.
A chest  X-ray  showed  bilateral  basal  patches  of
diminished  aeration  associated  with  bilaterally
accentuated bronchovascular  markings.  Labora-
tory studies  revealed  the  following:  a  leucocyte
9count of  4.8  ×  10 /L  with  predominant  neu-
trophils (80.6%);  a  hematocrit  of  40.1%;  a platelet
count of  163  × 109/L;  creatinine,  98  mol/L;  albu-
min,  27.4  g/L;  AST,  599  U/L;  and  ALT,  374  U/L.
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espiratory  and  blood  samples  were  collected  and
ent to  the  Jeddah  Regional  Laboratory  for  viral
tudies.
The patient  was  preliminarily  diagnosed  with
ommunity-acquired  pneumonia  and  was  put  on
00 mg  I/V  Avelox  (moxiﬂoxacin)  and  nebulization.
he various  drugs  used  for  nebulization  during  the
ourse of  the  patient’s  illness  were  as  follows:
.5 mg/2.5  ml  ampoules  Ventolin  (salbutamol)
very 4  h,  500  g/inhalation  solution  vial  Atrovent
ipratropium inhalation)  every  4  h and  1  mg/2  ml
uspension  Pulmicort  (budesonide  inhalation).  The
atient was  re-evaluated  the  next  day  and  was
rophylactically  administered  75  mg  oseltamivir
ID for  5 days  while  awaiting  laboratory  results.  On
ay 3,  the  patient  developed  shortness  of  breath
ith tachycardia.  The  oxygen  saturation  fell  to  83%
ith 5  liters  of  oxygen  and  repeat  nebulization.  The
atient’s temperature  continued  to  spike  to  39.8 ◦C
ith a  respiratory  rate  of  35breaths/min  and  a  pulse
f 105  beats/min.  On  chest  examination,  air  entry
as decreased  in  the  basal  zones,  and  arterial  blood
ases revealed  the  following:  a pO2 of  53.9,  a  pCO2
f  30.3  and  a pH  of  7.455.  The  ECG  was  normal.  The
atient developed  hypoxic  respiratory  failure  and
as transferred  to  the  intensive  care  unit  (ICU),
here  he  was  treated  for  acute  respiratory  distress
yndrome.  Non-invasive  mechanical  ventilation
as started.  Bilevel  positive  airway  pressure  was
rovided  with  an  initial  inspiratory/expiratory
ositive  airway  pressure  of  12/6  cm  of  water  that
as subsequently  increased  to  16/10  cm  of  water.
ethylprednisolone  was  also  added  to  the  treat-
ent regime.  Gradually,  the  patient’s  condition
mproved on  the  day  6,  and  he  was  weaned  off  the
echanical  ventilation  after  8 days.
aboratory results
he  blood  samples  were  sent  to  Jeddah  Regional
aboratory, which  is  the  reference  virology  lab-
ratory  that  performs  hemorrhagic  fever  panels
or viruses  that  are  prevalent  or  are  likely  to  be
ntroduced  into  the  Kingdom.  RT-PCR  for  dengue,
est Nile,  Alkhurma,  Rift  Valley,  Crimean  Congo
nd Chikungunya  viruses  (TIB  MOLBIOL,  GmbH,
ermany) was  carried  out.  Serotyping  was  per-
ormed  using  the  Dengue  LCD  array  1.5  (Chipron,
mbh, Berlin).  The  serology  for  dengue  was  per-
ormed  using  Panbio  kits  (Panbio  Diagnostics,
risbane, Australia).  The  nasopharyngeal  swabs
ere tested  for  H1N1  using  the  Real  Time  ready  RNA
irus Master  &  Real  Time  ready  Inﬂuenza  A/H1N1
etection set  (Roche).  The  NA  gene  of  the  inﬂuenza
T rus  
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Rhe  diagnostic  challenge  of  pandemic  H1N1  2009  vi
irus  was  screened  for  the  H275Y  mutation  which
s responsible  for  oseltamivir  resistance,  with  the
rimer Design  kit  (UK).
Dengue  RNA  was  detected  in  the  blood  sam-
les, and  serotyping  revealed  type  2  dengue  virus.
he serology  for  dengue  was  negative  for  IgM,  IgG
nd NS1  antigens.  The  inﬂuenza  A  pandemic  2009
1N1 strain  was  detected  in  the  nasopharyngeal
wabs. As  the  patient  was  in  respiratory  failure  in
he ICU,  a  repeat  nasopharyngeal  swab  was  sent
o the  laboratory  after  7  days,  and  the  inﬂuenza
 pandemic  H1N1  2009  strain  was  still  detected.
s the  inﬂuenza  virus  persisted,  the  samples  were
creened  for  the  H275Y  mutation,  but  the  isolated
1N1  strain  was  found  to  be  the  wild-type  strain
nd not  the  mutant  strain.
iscussion
ifferentiating  between  dengue  fever  and  inﬂuenza
ased  on  clinical  features  alone  is  difﬁcult  and
equires  laboratory  conﬁrmation.  This  patient  pre-
ented with  certain  symptoms  that  are  consistent
ith dengue  fever,  such  as  fever,  myalgia,  and  sore
hroat, but  certain  features  that  are  considered  to
e hallmarks  of  the  disease,  such  as  rash,  retro-
rbital  pain,  gastrointestinal  symptoms,  petechiae
r bleeding,  were  not  present.  In  addition,  there
as no  thrombocytopenia,  and  the  tourniquet  test
as negative.  Therefore,  it  was  difﬁcult  to  distin-
uish  dengue  fever  from  inﬂuenza  and  other  febrile
llnesses.
The combination  of  dengue  fever  and  inﬂuenza
s usually  not  reported,  although  both  present  as
ebrile illnesses.  The  clinical  syndrome  of  each
isease  is different:  inﬂuenza-like  illness  and  pneu-
onitis in  pandemic  inﬂuenza  vs  hemorrhagic
anifestations  in  dengue  fever.  The  management  of
he two  diseases  is  also  different:  supportive  ther-
py for  dengue  fever  and  oseltamivir  for  pandemic
nﬂuenza.  Clinically,  the  patient  was  diagnosed
ith community-acquired  pneumonia  and  empiri-
al antibiotic  treatment  was  started,  to  which  he
id not  respond.  Oseltamivir  was  later  added  for
nﬂuenza,  but  dengue  was  not  the  initial  diagnosis.
Persistent  viral  shedding  (PVS)  has  been  deﬁned
s the  detection  of  inﬂuenza  A  H1N1  virus  by  real-
ime PCR  on  day  7  after  the  initial  diagnosis  and
as been  associated  with  risk  factors  that  include
dmission  to  the  ICU,  purulent  expectoration,  cor-
icosteroid  treatment  and  mechanical  ventilation
16]. These  factors  were  consistent  with  the  ﬁnd-
ngs of  this  patient.  PVS  has  been  demonstrated
n hospitalized  patients  for  both  seasonal  andin  a  dengue-endemic  region  201
andemic  inﬂuenza  in  22—57%  of  patients  7  days
fter onset  of  illness  [17,18].  The  PVS,  however,
aised the  suspicion  that  the  pandemic  H1N1  2009
train was  oseltamivir  resistant;  therefore,  the
amples  were  screened  for  the  H275Y  mutation.
he strain  turned  out  to  be  the  wild-type  strain
nd not  the  mutant  oseltamivir-resistant  strain  with
he H275Y  mutation.  The  viability  of  the  virus  and
ts transmission  after  7 days  of  illness  has  been
escribed  in  a few  studies  [19].
Co-infection  with  dengue  fever  and  H1N1  has
een reported  in  tropical  countries  and  territo-
ies, such  as  Nicaragua  [20,21],  Vietnam  [22]  and
uerto Rico  [23],  but  the  disease  distribution  in
eddah, Saudi  Arabia,  is  very  different  from  that  in
ther parts  of  the  world.  Jeddah  is  the  gateway  of
ntry into  the  Kingdom  of  Saudi  Arabia  for  multiple
ationalities  throughout  the  year  for  the  holy  pil-
rimage to  Makkah  and  is  also  the  point  of  entry  for
 multitude  of  pathogens  carried  by  these  visitors.
his ﬁrst  laboratory-conﬁrmed  case  of  dengue  fever
nd inﬂuenza  A  pandemic  H1N1  2009  virus  high-
ights the  importance  of  considering  co-infections,
s such  cases  are  a diagnostic  challenge  especially
n Jeddah,  Saudi  Arabia,  where  several  viral  hemor-
hagic fever  viruses  are  suspected  to  circulate.  It  is
ot possible  to  distinguish  these  viral  hemorrhagic
ever viruses  from  each  other  or  from  other  febrile
llnesses based  solely  on  the  clinical  features.
onclusion
e  report  the  ﬁrst  case  of  co-infection  with
nﬂuenza A  H1N1  and  dengue  fever  in  Saudi  Arabia
nd describe  the  associated  diagnostic  challenges.
e also  demonstrated  that  our  patient  exhibited
ersistent viral  shedding  and  suggest  that  further
tudies  regarding  the  respiratory  isolation  of  H1N1
e conducted.  We  also  recommend  that  testing  be
erformed for  both  viruses  in  regions  where  they
o-circulate  in  population.
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